InvestSMART

4DMedical Limited (ASX: 4DX) - ETF Exposure

Current share price for 4DX : $4.340 0.02 (0.46%)+

4DMedical Limited (4DX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company engaged in medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging.

4DX General Information +

ASX Code 4DX
Website N/A
Industry/Sector Health Care Technology
Market Cap ($M) 2,610
4DX Share Price $4.340
Day High $4.590
Day Low $4.340
Last Close $4.360
4DX Share Price Movement $0.02 ( 0.46% )
Prices as at 16:40, 2 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to 4DX

As a significant Australian company by market capitalisation, 4DX is held across 18 ETFs spanning strategies that include health care technology exposure . Its weighting in those funds means performance can have an outsized influence - when 4DX moves, funds like ALFA, ATEC, ISO, SSO and MTUM that hold it can move with it.

For more concentrated exposure, ETFs such as ALFA (Vaneck Australian Long Short Complex ETF) allocate about 2.8% to 4DX , while the average exposure across all 18 ETFs that hold it is around 0.5% .

Top ETF holdings

Last updated: ETF data and holdings as at 3 October 2026

Own 4DX directly or through an ETF?

How does holding 4DMedical Limited (4DX) shares directly compare to ETFs that include it?

4DX Direct
ALFA
ASX
ATEC
ASX
ISO
ASX
SSO
ASX
MTUM
ASX
Holdings 1 company 105 holdings 49 holdings 218 holdings 219 holdings 104 holdings
4DX Weight 100% 2.8% 1.4% 0.8% 0.8% 0.4%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.39% p.a. 0.48% p.a. 0.55% p.a. 0.5% p.a. 0.35% p.a.
Approx. Yield 0% 0.88% 1.92% 4.41% 9.39% 2.2%
Star Ratings - star starstarstarstar starstarstar starstar starstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not 4DX's direct yield. Annual cost uses each ETF's MER.

4DX Exposure on $10,000 investment

How a $10,000 investment in 4DMedical Limited (4DX) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
4DMedical Limited (4DX) Direct share $4.340 8.50% +$850 $10,850
Vaneck Australian Long Short Complex ETF (ALFA) Equity - Australia Strategy $22.710 -0.48% -$48 $9,952
BetaShares S&P/ASX Australian Technology ETF (ATEC) Equity - Australia Sectors $21.490 4.17% +$417 $10,417
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) Equity - Australia Small/Mid Cap $4.960 -1% -$100 $9,900
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) Equity - Australia Small/Mid Cap $14.280 -0.97% -$97 $9,903
Betashares Australian Momentum ETF (MTUM) Equity - Australia Strategy $27.630 -0.04% -$4 $9,996

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

4DMedical Limited (4DX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from 4DMedical Limited (4DX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

4DMedical Limited (4DX) price-sensitive announcements

4DX - Quarterly Activity Report and Appendix 4C
4DMedical Limited has released its Quarterly Activity Report and Appendix 4C for the quart
4DMedical Limited (4DX)
31 Jul 2026 | 10:13 AM
4DX - US Bill directs VA to adopt 4D lung imaging
4DMedical Limited announced the introduction of a bipartisan bill in the US House of Repre
4DMedical Limited (4DX)
16 Jul 2026 | 12:31 PM
4DX - Trading Halt
4DMedical Limited (ASX: 4DX) requested a trading halt on its securities from the Australia
4DMedical Limited (4DX)
16 Jul 2026 | 10:45 AM
4DX - Pause in trade
On 16th July 2026, the Australian Securities Exchange (ASX) announced a temporary pause in
4DMedical Limited (4DX)
16 Jul 2026 | 10:00 AM

4DMedical Limited (4DX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
4DMedical Limited (4DX)
ORDINARY FULLY PAID
Health Care $2,611 Notification of cessation of securities - 4DX 2 Oct 2026 4:22PM $4.340 $4.340 fallen by 0%
4DMedical Limited (4DX)
ORDINARY FULLY PAID
Health Care $2,611 Application for quotation of securities - 4DX 2 Oct 2026 4:20PM $4.340 $4.340 fallen by 0%
4DMedical Limited (4DX)
ORDINARY FULLY PAID
Health Care $2,611 Ceasing to be a substantial holder 28 Sep 2026 8:16AM $4.000 $4.340 risen by 8.50%
4DMedical Limited (4DX)
ORDINARY FULLY PAID
Health Care $2,611 Becoming a substantial holder 25 Sep 2026 8:12AM $4.100 $4.340 risen by 5.85%
4DMedical Limited (4DX)
ORDINARY FULLY PAID
Health Care $2,611 Notice of Annual General Meeting/Proxy Form 24 Sep 2026 9:37AM $4.080 $4.340 risen by 6.37%
4DMedical Limited (4DX)
ORDINARY FULLY PAID
Health Care $2,611 Appendix 4G and Corporate Governance Statement 24 Sep 2026 9:28AM $4.080 $4.340 risen by 6.37%

4DX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$204.38 -$38.10 178.20% 0.00 0.00 0.00% 0.0%
2025A -$29.41 -$13.70 33.00% 0.00 0.00 0.00% 0.0%
2024A -$33.66 -$10.30 -1.90% 0.00 0.00 0.00% 0.0%

4DX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
4DMedical Limited (4DX) $2,623M 1.7823 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Artrya Limited (AYA) $561M -0.0450 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Pro Medicus Limited (PME) $16,829M 1.3034 -0.2811 0.2395 63.5213 88.3605 71.2851 0.43% 0.57% 0.71%

4DX Directors

Name Position Start Date
Dr Andreas Fouras Chief Executive Officer, Managing Director 17 Dec 2012
Mr Julian Bernard Kingsley Sutton Chief Financial Officer, Executive Director, Executive Chairman 15 Sep 2017
Mr John Andrew Livingston Executive Director 7 Mar 2018
Dr Robert Alan Figlin Non-Executive Director 9 Dec 2016
Dr Geraldine Bernadette McGinty Non-Executive Director 25 Sep 2023
Professor Christine Jenkins Non-Executive Director 23 Sep 2026
Ms Lilian (Lil) Bianchi Non-Executive Director, Non-Executive Chairman 11 Dec 2019

4DMedical Limited (4DX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
19 Jun 2026 SUTTON, Julian Buy Direct Shares 11,363 $4.400 $49,997.200
18 Jun 2026 SUTTON, Julian Buy Direct Shares 13,054 $3.830 $49,996.820
21 Jan 2026 FOURAS, Andreas Sell Indirect Shares 263,157 $3.800 $999,996.600

See all changes in directors' interest & trades for 4DMedical Limited (4DX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

4DX Management

Name Position
Matt Tucker CCO
Hamish George Company Secretary

4DX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in 4DMedical Limited (4DX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
67,289,222 (11.19%) Velocimetry Consulting Pty Ltd

4DX Calendar of Events

Date Event
23 September 2027 Report (Annual)
27 August 2027 Report (Prelim)
26 February 2027 Report (Interim)
28 October 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.